Broad-spectrum therapeutics for influenza is critically needed to address the problem of influenza pandemics, a major threat to the public health globally. We have proposed studies aiming at identifying molecules that are capable of blocking infections of all strains of influenza viruses by targeting the host factors which are essential for activation of all influenza viruses. In this proposed phase I study, we will generate the drug candidates, charactering and compare their biochemical and functional activities in vitro. Our goal is to have two final candidates identified and ready for further preclinical evaluation in phase II study.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
5R43AI062178-02
Application #
6898717
Study Section
Special Emphasis Panel (ZRG1-SSS-Z (10))
Program Officer
Lacourciere, Karen A
Project Start
2004-06-01
Project End
2007-05-31
Budget Start
2005-06-01
Budget End
2007-05-31
Support Year
2
Fiscal Year
2005
Total Cost
$387,459
Indirect Cost
Name
Nexbio, Inc.
Department
Type
DUNS #
140600268
City
San Diego
State
CA
Country
United States
Zip Code
92121